Health-tech startup Dectrocel has raised Rs 4 crore in a funding round led by IAN Group-powered BioAngels, with additional participation from PadUp Ventures and Vinners. Key IAN investors in this round include Nitin Zamre, Samir Kalia, and Mitesh Shah.
The fresh funds will be utilised to scale commercial operations across India, enhance its self-learning multimodal AI technology, expand into international markets, and accelerate the launch of new AI tools in CT, MRI, PET-CT, and HPB diagnostic modules, the company said.
Founded in 2020 by Ankit Shukla, Saumya Shukla, and Nikhil Mishra, the Lucknow-based health-tech company Dectrocel develops AI-powered diagnostic solutions for respiratory and hepato-pancreatico-biliary (HPB) diseases.
Dectrocel’s flagship product, DecXpert, is one of only three AI-based diagnostic tools approved for clinical use in India by CDSCO. It delivers chest X-ray and CT-scan interpretations that are 10x faster with 98% accuracy.
Also Read | RxMen Raises ₹5 Cr Seed Funding Led by IPV
The platform helps bridge India’s acute shortage of radiologists (1:125,000 ratio), particularly in tier-2 and tier-3 cities where diagnostic delays of 7–10 days and error rates of 25–40% are common.
Going forward, the company plans to expand commercial deployment of DecXpert through OEM partner networks, target India’s Rs 1,000 crore digital X-ray market, and establish an early presence in Southeast Asia. It is also working on new diagnostic modules for advanced imaging and HPB diseases, while enhancing its AI for broader pathology detection and self-learning adaptability.
